Egalet's Arymo ER Opioid Has Questionable Oral Abuse-Deterrent Effect

Drug liking score in human oral abuse study shows small but statistically significant difference, and clinical relevance is unclear, FDA says in advisory committee briefing documents.

FDA's evaluation of the abuse-deterrence properties of Egalet Corp.'s Arymo ER (morphine sulfate extended-release) suggests an oral deterrence claim may be the hardest to come by for the long-acting opioid.

Arymo has been formulated with physicochemical properties intended to deter abuse by the oral (chewing and crushing), intranasal and intravenous...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers